Background: Previous studies indicate high prevalence of liver diseases in HIV-infected patients, and their genetic risk factors are still unclear. The chemokine CXCL12 plays important roles in development of chronic liver injury and a single nucleotide polymorphism (SNP) G to A change at position 801 in CXCL12 gene has been demonstrated to affect CXCL12 production levels.
Background
Human immunodeficiency virus (HIV) infection continues to be a major heath issue with estimated 36.7 million people living with HIV worldwide at the end of 2015. 1 During the last decade, the advances in management of HIV-infected patients with combined anti-retroviral therapy (ART) have led to a decrease of acquired immunodeficiency syndrome (AIDs)-related morbidity and mortality with an increased evidence of liver-related diseases. Various factors can cause liver damage in HIV-infected patients including HIV replication in the liver, hepatitis B or C virus (HBV or HCV) coinfection, anti-retroviral therapy (ART), immune reconstitution and opportunistic infections. 2, 3 Viral hepatitis has been shown to be the most common risk of liver-related illness in HIV patients. [2] [3] [4] Published studies in HIV-monoinfected and hepatitis infections including tuberculosis, were excluded. 2, 23 All subjects provided written informed consent and the study protocol was reviewed and approved by the Human Ethics Committees No. 2, Thammasat University, Thailand (Project no. 077/256).
Clinical and laboratory data were obtained as described in the previous study. 7 Briefly, the data collected from patient's medical records and standardized questionnaire were age, gender, duration of antiretroviral therapy (ART), currently used anti-retroviral (ARV) regimens, opportunistic infections, alcohol consumption, herbal medicine and steroid intake. All patients underwent clinical examination and routine blood tests including levels of aspartate and alanine aminotransferases (AST and ALT), platelet count, anti-HCV, HBsAg, and CD4 + cell count. Additionally, ethylene-diamine-tetra-acetic acid (EDTA) blood samples left over from routine testing were subjected to plasma separation within 8 hours after blood collection and stored at -80°C until use.
Genotyping of CXCL12 G801A polymorphism
Genomic DNA was extracted from EDTA blood samples using a Nucleospin® blood extraction kit (Macherey-Nagel GmbH, Duren, Germany) according to the manufacturer's instruction. DNA samples were genotyped for CXCL12 G801A or SDF1-3' A (rs1801157) polymorphism using a polymerase chain reaction-sequence specific primer (PCR-SSP) assay developed in the previous studies. 24, 25 Two pairs of specific primer sets were used. Firstly, an A allele-specific primer pair comprises forward inner (5' CATCCACATGGGAGCCA 3') and reverse outer primers (5' ACATTGGTCACAGAGGAGGA 3') producing a 364 bp PCR product. Secondly, a G allele-specific set is composed of forward outer (5' GCTCTGAAACCAGT-GTTAGG 3') and reverse inner primers (5' CCAGAAGAGG-CAGACCC 3') producing a 495 bp PCR product. The two sets of primers also amplify a PCR product of 826 bp from the two outer primers. DNA samples (25-50 ηg) were amplified using the PCR kit buffer plus 0.25 U of Tag DNA polymerase (NanoHelix, Deajeon, South Korea). PCR conditions were as follows: denaturation at 94°C for 2 min, 35 cycles of 95°C for 20 sec, 64.5°C for 50 sec, and 72°C for 1 min, and elongation at 72°C for 5 min in a T100 Thermal Cycler (Bio-Rad, Hercules, CA). PCR products were then analyzed by electrophoresis in 2% agarose gel with DNA size marker of 100-1,000 bp and visualized using UV fluorescence after staining with ethidium bromide. Positive DNA controls with possible genotypes and negative control with no DNA were included in a panel of genotyping. 24 As shown in Figure 1 , the GG and AA genotypes yielded 495 and 364 bp PCR products respectively while the GA heterozygous genotype presented both 495 and 364 bp products. Samples of all genotypes exhibited the 826 bp internal control fragments. Thirty four (34) of 164 PCR samples (20.7%) with 8/164 AA, 11/164 GA and 15/164 GG genotypes were subjected to direct DNA sequencing and analyzed by Unipro UGENE v.1.24.2. There was 100% agreement between the results obtained by PCR-SSP and by direct sequencing.
Evaluation of liver complication
From routine laboratory data, several surrogate markers were used to determine liver abnormality in HIV patients including thrombocytopenia, transaminitis, fibrosis-4 (FIB-4) CXCL12 G801A SNP and liver fibrosis 163 virus-coinfected patients have also identified multiple risk factors for development and severity of liver disease including HIV RNA levels, CD4 + cell count, increased body mass index, duration and types of ART, severe alcohol use, diabetes mellitus and host genetic polymorphisms. [5] [6] [7] [8] Presently, even though studies have revealed some genetic and immunological parameters influencing liver disease progression specifically in HCV/HIV-coinfected patients, 8 host genetic determinants of liver disease in HIV infection are required more investigation.
Chemokine systems play important roles in the recruitment of immune cells to the liver, regulating immune cell infiltration, chronic inflammation and progression of fibrosis. 9 One of the most interesting systems is CXCL12 or stromal cell -derived factor-1 (SDF-1) and its respective receptors CXCR4 and CXCR7. The CXCL12/CXCR4/CXCR7 system is known to regulate liver homeostasis, and their increased expression are involved in acute liver injury, chronic liver damage or fibrosis, and hepatocellular carcinoma (HCC) development and metastasis. 9, 10 Apparently, the common polymorphism in CXCL12 gene, a single nucleotide polymorphism (SNP) G to A change at position 801 in the 3'untranslated region (UTR) of an alternatively spliced mRNA transcript, also termed SDF-13' A or rs1801157, has been reported to affect levels of CXCL12 production in vitro and in vivo. [11] [12] [13] Up to date, only few studies have investigated roles of CXCL12 gene polymorphisms in liver diseases. SNPs in CXCL12 gene have been demonstrated to influence occult HBV infection, therapeutic responses in HCV/HIV coinfection, and susceptibility and pathological development of hepatocellular carcinoma (HCC), [14] [15] [16] but lack of significant association with death and HCC occurrence in HCV-related and alcoholic cirrhosis. 17, 18 CXCL12 is also well known to contribute dramatically to pathogenesis and progression of HIV infection and many previous studies have indicated an impact of CXCL12 gene polymorphisms including the G801A SNP on resistance of HIV infection, progression to AIDs and responses to ART. 11, 13, [19] [20] [21] [22] However, influence of the CXCL12 gene polymorphism on chronic liver diseases developed in HIV-infected patients is still unknown.
Our previous study has demonstrated a high prevalence of transaminitis in Thai HIV-infected patient group with high rates of HBV and/or HCV coinfection and mostly on long -term suppressive ART, suggesting their potential to develop chronic liver injury. 7 The present study therefore aimed to investigate an impact of CXCL12 G801A polymorphisms on hepatic complications of these patients. Frequencies of CXCL12 G801A alleles and genotypes, and their association with liver abnormalities were examined. Risk factors for liver complications in this HIV patient group were also determined using logistic regression analyses.
Materials and Methods

Study population
A cross-sectional study was conducted in 164 HIV patients attending the Antiretroviral Therapy Clinic in Nakorn Nayok Hospital from October 2011 to June 2013. In this study, inclusion criteria were as follows: patients with documented HIV infection, and availability of blood samples and clinical data. Patients who regularly consumed alcohol, herbal medicine, steroid medication, and patients with active opportunistic score and AST-to-platelet ratio index (APRI). Platelet count was utilized to assess thrombocytopenia which was classified into 4 grades. 75,000 to 150,000/μL were defined as grade 1, 50,000 to < 75,000 /μL as grade 2, 25,000 to < 50,000 /μL as grade 3 and < 25,000 /μL as grade 4. 26, 27 Transaminitis was defined as an increased level from the normal upper limit (ULN) of either AST or ALT (> 40 U/L).
7 FIB-4 score was calculated and classified into class 1 (< 1.45), class 2 (1.46 to 3.25) and class 3 (> 3.25).
28,29 APRI value was calculated and classified into class 1 (< 0.5), class 2 (0.51 to 1.5) and class 3 (> 1.5).
30
Statistical Analysis
Genotype and allele frequencies were calculated by direct counting. Hardy-Weinberg equilibrium was assessed using χ 2 test with one degree of freedom from online analysis tools, considering equilibrium when p > 0.05. 31 χ 2 test or Fishers's exact test, and odds ratio with 95% confidence interval (CI) were used to determine an association of CXCL12 G801A genotypes with categorical variables. The level of statistical significance was determined at p < 0.05. Univariate and multivariate logistic regression were performed to determine risks for the liver complication assessed by transaminitis and APRI > 0.5. Odds ratio (OR) with 95% confidence interval (CI) and P value were calculated. All P values < 0.05 were considered as statistically significant. The PASW statistics 18 software (SPSS Inc.) was used for statistical analysis.
Results
Characteristics of the study population
Characteristics and clinical features of the subjects are summarized in Table 1 HIV-infected patients were evaluated for liver complication using available noninvasive markers as shown in Table 1 . In the 147 HIV patients with a mean platelet count of 276 (±105) × 10 9 /μL, 10 (6.8%) patients were assessed as having grade 1 or 2 thrombocytopenia. Of the 143 patients, 40 (28.0%) had transaminitis, 20 (14.0%) were assessed as having class 2 or 3 APRI (APRI > 0.5) and 27 (18.9%) were classified as class 2 or 3 (FIB-4 score > 1.45).
Genotypic and allelic distribution of CXCL12 G801A polymorphism and association with liver complication in HIV-infected Thais
As shown in Table 2 , 93 (56.7%), 58 (35.4%) and 13 (7.9%) patients were detected with GG, GA and AA genotypes and frequencies of G and A alleles were 0.744 (244) 
CXCL12 G801A polymorphism as a predictive factor for liver complication in the ART-naïve patients
To examine possible risk factors for liver abnormalities assessed by transaminitis and APRI in this study population, logistic regression analyses were conducted on variables which were CXCL12 G801A genotypes, gender, age, CD4 + cell count, hepatitis B and/or C virus coinfection, navirapine experience and ART duration as shown in Table 3 . Univariate analysis of risk factors for transaminitis indicated that being male, coinfection with HBV and/or HCV and the CXCL12 G801A AA/ GA genotypes were risk factors for developing transaminitis (OR 3.7, 95%CI 1.6-8.4, p = 0.002, OR 3.3, 95%CI 1.3-8.9, p = 0.015 and OR 2.5, 95%CI 1.2-5.3, p = 0.015, respectively). In subsequent multivariate analysis, only coinfection with HBV and/or HCV was predictive for transaminitis in this study group (OR 3.1, 95%CI 1.1-8.6, p = 0.035). In univariate analysis of risk factors for having APRI > 0.5, several factors including being male, age older than 40 years, having CD4 + cell count To further analyze a possible influence of ART on the genetic effect of CXCL12 G801A polymorphism observed, clinical data indicating hepatic function and HIV disease severity including CD4 + cell count, levels of AST and ALT, platelet count, APRI and FIB-4 score in the HIV patients possessing AA/GA were compared with those having GG genotypes, in all HIV -infected patients, ART-naïve and ART-experienced groups, as demonstrated in Table 4 . In all 164 HIV patients, the patients with AA/GA had significantly higher levels of AST than those with GG genotypes (p = 0.018) and there were no significant differences in other markers (p > 0.05). Data analysis in ARTnaïve patients indicated that the medians of AST levels, APRI and FIB-4 score were significantly higher in the patients having AA/GA than those possessing GG genotypes (p = 0.003, p = 0.018 and p = 0.022 respectively). When compared with those having GG, the patients with AA/GA had relatively lower median of CD4 + cell count, even though the difference was not significant (p = 0.062). In contrast, there were no significant differences in all serum markers observed in the ART-experienced group (p > 0.05). The data indicated that CXCL12 G801A genotypes had an effect on liver complication only in the ARTnaïve patients, suggesting influence of ART on the predictive ability of the G801A genotypes in this study group.
Discussion
This cross-sectional study was conducted in 164 HIV patients maintaining high CD4 + cell count. There were high prevalence rates of HBV and HCV coinfection and high percentages of patients with long suppressive ART especially hepatotoxic nevirapine-containing regimens. Evaluation of liver abnormalities by non-invasive laboratory test available in this study indicated that there were high rates of patients with thrombocytopenia (6.8%), transaminitis (28.0%), significant fibrosis as shown by FIB-4 score > 1.45 (18.9%) and by APRI > 0.5 (14.0%) consistent with previous studies reporting prevalence of liver fibrosis in HIV-monoinfected and HCV-coinfected patients. 6, 32 Our analysis indicated a high prevalence of HIV patients with chronic hepatic injury, which possibly develop to more severe fibrosis and cirrhosis as observed in the studies in HIV patients who were coinfected with HCV and on ART for longer duration. 32, 33 CXCL12 G801A polymorphism has been well characterized in different ethnic groups and established to have an impact on susceptibility to HIV infection, HIV disease progression and ART response 11, 13, [19] [20] [21] [22] whereas few studies indicate its role in liver disease caused by hepatitis viruses and hepatocellular carcinoma. 14, 16 In this study, frequency of the A allele of CXCL12 G801A polymorphism was observed as 0.256 while previous studies in Thai HIV-seropositive patients and blood donors reported the frequencies ranging from 0.199-0.43. 20, 21 The CXCL12 G801A genotypes were in Hardy-Weinberg equilibrium (p > 0.05), indicating that genetic background of the Table 4 
Conclusion
This cross-sectional SNP analysis provides the evidence that the presence of CXCL12 G801A SNP is associated with development of liver complication probably in the ART-naïve HIV-infected Thais. Specifically, the patients having the unfavorable G801A AA/GA had a significantly higher risk for significant liver fibrosis than those carrying GG genotypes. This finding might provide a new molecular genetic mechanism for liver disease in HIV patients. A further prospective study in a larger number of patients is required to verify our finding.
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No conflict of interest is declared. study population remains constant. Our data indicated significant associations of the CXCL12 G801A SNP with transaminitis and significant hepatic fibrosis assessed by APRI > 0.5. While univariate analysis suggested the G801A AA/AG genotypes as risk factors for transaminitis, subsequent multivatiate analysis indicated no longer significant risk of the genotypes. However, the analyses have identified the G801A AA/GA genotypes as risk factors for significant liver fibrosis by APRI and it is apparent that the patients with AA/GA carries 6.8 times higher risk than those with GG genotypes. Interestingly, additional analysis demonstrated the significant higher medians of AST, APRI and FIB-4 score, with the relatively lower CD4 + cell count, in patients possessing the AA/GA than those having GG genotypes observed only in the ART-naïve, but not in ART-experienced HIV patient groups. Notably, distribution of the G801A AA/GA and GG genotypes in the ART-naïve and in ART-experienced patients are similar (p > 0.05) (data not shown). Collectively, the results suggest a strongly significant effect of the G801A AA/GA genotypes on liver abnormalities during HIV infection, and this effect can possibly be lessened by ARV treatment. Mechanisms for the neutralization of this genetic effect by ART are unclear and remain to be elucidated. To the best of our knowledge, this is the first evidence implicating the CXCL12 G801A polymorphism in the development of liver fibrosis in HIV-infected patients.
Functional roles of the CXCL12 G801A SNP have been studied in several diseases including HIV infection, but have not been clearly described in liver diseases. The G801A SNP is known to be located in a segment of the 3'UTR of β isoform transcript that may serve as a target for cis-acting factors promoting synthesis of CXCL12. 11 The in vitro study demonstrated that the 3' A genotype leads to an enhanced CXCL12 mRNA stability and therefore increases levels of the CXCL12 mRNA production. 12 The in vivo effect of the G801A SNP on CXCL12 production has also been demonstrated in HIV infection, 13, 20 even though its mechanistic roles in susceptibility and disease progression are still controversial and not completely clear. 11, 13, 19 In liver microenvironment, CXCL12 is constitutively produced mainly by biliary epithelial cells and apparently upregulated during fibrotic injury, leading to an elevation of plasma CXCL12 levels in the patients with chronic liver inflammation and fibrosis whereas over 50% of liver infiltrating cells are CXCR4 positive. 34 In chronic liver injury, CXCL12 is increasingly expressed and activates CXCR4 on liver sinusoidal endothelial cells, triggering a profibrotic response, and induces hepatic stellate cells (HSC) proliferation and activation, leading to α-smooth muscle actin and collagen production. CXCL12 also attracts mesenchymal stem cells from the bone marrow that can promote liver fibrosis. 10 Accordingly, production of CXCL12 particularly in the liver area, which is possibly released into circulation, may influence hepatic fibrogenesis and therefore affecting progression of chronic liver diseases. Thus, an influence of the CXCL12 G801A genotypes on significant fibrosis observed in our HIV-infected patients may be due to their effect on the CXCL12 expression and function during chronic liver injury.
As there were multiple factors possibly associated with liver abnormalities in this study group, logistic regression analysis for risks of liver complication was adjusted for characteristics of patients including gender, age, CD4 + cell count, HBV and/ or HCV coinfection, CXCL12 G801A genotypes, navirapine experience and ART duration in the model. Consistent with the findings in our previous study, 7 HBV and/or HCV coinfection remains a risk factor for transaminitis in this study group. Apart from the G801A AA/GA genotypes, other predictive factors for significant liver fibrosis in this study group including age older than 40 years, CD4 + cell count < 350 cells/µl and HBV and/or HBV coinfection were also identified. These risk factors are probably different from many previous studies due to differences in the study design, characteristics of study population, outcome variables, ARV drug regimens and duration of ART. 2, 3, 5, 6, 35 However, it is important to note limitations of this study. Firstly, a cross-sectional study design is usually unable to control confounding factors although the multivariate regression analysis was applied to this association study. Besides, this study design may not allow determining the precise effect of particular ARV drugs on hepatic abnormalities because the patients possibly have been switched from other regimens. Secondly, this study contains a limited number of subjects and missing values in some variables, which may limit statistical significance for the variables tested. Thirdly, there is no functional assessment of the G801A genotypes in this study and further evaluation of CXCL12 activities both in circulation and hepatic area is suggested. Fourthly, haplotype analysis of the rs1801157, G801A SNP, along with other SNPs in the 3' UTR of CXCL12 gene such as rs1029153 should be performed to confirm its significance in the liver complication in HIV infection. Lastly, this effect of the G801A SNP on liver complication was analyzed only in Thai patients and it would be interesting to extend the analysis to different ethnic groups.
